Biotech entity
Every one of those 1 sits in a single category, clinical-trial. Outsourcing in Clinical Trials Conference is most often covered alongside Chinese biotech industry, which appears in 1 of these 1 story. Outsourcing in Clinical Trials Conference appears in 1 tracked Biotech story from June 24, 2026.
Last mentioned: Jun 24, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, clinical-trial. Outsourcing in Clinical Trials Conference is most often covered alongside Chinese biotech industry, which appears in 1 of these 1 story. Outsourcing in Clinical Trials Conference appears in 1 tracked Biotech story from June 24, 2026. The tracked stories average 2 original sources each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 1 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Outsourcing in Clinical Trials Conference. Shared-story counts are live from our verified record — not editorial picks.
NMPA releases 2025 report
China's National Medical Products Administration publishes comprehensive statistics on the record-breaking clinical trial activity.
Cost advantages quantified
At the Outsourcing in Clinical Trials conference in California, China's trial costs were reported 50–60% lower and timelines faster than in the US.
Record trial count achieved
5,215 clinical drug trials registered, more than double 2020, with 57.5% being new drug trials and cancer treatments dominating.
Pre-surge baseline
Approximately 2,600 clinical drug trials registered in China (implied by 2025 doubling).
With 5,215 clinical drug trials registered in 2025, China has more than doubled its pipeline since 2020, with 57.5% focused on novel drugs and cancer treatments topping the list. The rapid expansion and 50–60% cost advantage compared to the US are reshaping the global biopharma landscape, but Washington is scrutinizing implications for drug quality and security.
Source: Julie Zhang (hk) · Julie Zhang (hk)
Outsourcing in Clinical Trials Conference is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
